Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02VIP
|
||||
| Former ID |
DIB012544
|
||||
| Drug Name |
SB-267268
|
||||
| Synonyms |
2-[3-Oxo-8-[3-(2-pyridylamino)propoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4(S)-yl]acetic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Discontinued in Phase 1 | [547185] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H24F3N3O4
|
||||
| Canonical SMILES |
C1C(C(=O)N(CC2=C1C=CC(=C2)OCCCNC3=CC=CC=N3)CC(F)(F)F)CC<br />(=O)O
|
||||
| InChI |
1S/C22H24F3N3O4/c23-22(24,25)14-28-13-17-11-18(32-9-3-8-27-19-4-1-2-7-26-19)6-5-15(17)10-16(21(28)31)12-20(29)30/h1-2,4-7,11,16H,3,8-10,12-14H2,(H,26,27)(H,29,30)/t16-/m0/s1
|
||||
| InChIKey |
PVDGZHKJXXVONO-INIZCTEOSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Integrin alpha-V/beta-3 | Target Info | Modulator | [528102] | |
| Integrin alpha-V/beta-5 | Target Info | Modulator | [528102] | ||
| WikiPathways | Osteoblast Signaling | ||||
| Focal Adhesion | |||||
| Class I MHC mediated antigen processing & presentation | |||||
| Syndecan interactions | |||||
| Extracellular matrix organization | |||||
| Elastic fibre formation | |||||
| Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
| Integrin-mediated Cell Adhesion | |||||
| L1CAM interactions | |||||
| Integrin cell surface interactions | |||||
| Cell surface interactions at the vascular wall | |||||
| Osteopontin Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.